

Curriculum Vitae

Thomas E. Eissenberg, Ph.D.

Professor

Department of Psychology and Institute for Drug and Alcohol Studies
Director, Clinical Behavioral Pharmacology Laboratory
Virginia Commonwealth University
Box 980205, Richmond, Virginia 23298-0205
(804) 827-4617
e-mail: teissenb@vcu.edu

- Current Position** Professor, July, 2008 to present. Department of Psychology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia, U.S.A.
Director, Clinical Behavioral Pharmacology Laboratory, Virginia Commonwealth University, Richmond, Virginia, U.S.A.
- Educational History** Post-Doctoral Fellow, June 1994 to June 1996. Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
Ph.D. in Experimental Psychology, 1994. Department of Psychology, McMaster University, Hamilton, Ontario, Canada.
B.A. in Psychology and English, 1987. Grinnell College, Grinnell, Iowa, U.S.A.
- Previous Academic Appointments** Associate Professor, Virginia Commonwealth University. July, 2002 to July, 2008.
Assistant Professor, Virginia Commonwealth University. July, 1997 to July, 2002.
Instructor, Johns Hopkins University School of Medicine. July, 1996 to July, 1997.
Instructor, Mount Allison University (Sackville, New Brunswick). August, 1993 to June, 1994.
Instructor, McMaster University (Hamilton, Ontario). Summer, 1992 and Summer, 1993.
- Current Joint Appointments** Departments of Internal Medicine, Pharmacology and Toxicology, and Psychiatry, Virginia Commonwealth University.
Division of Addiction Psychiatry, Virginia Commonwealth University.
Institute for Drug and Alcohol Studies, Virginia Commonwealth University.
Member Scientist, Massey Cancer Center, Virginia Commonwealth University.
- Professional Affiliations** American Psychological Association (Fellow, Division 28, September, 2007)
American Psychological Society
College on Problems of Drug Dependence
Society for Research on Nicotine and Tobacco
- Research Support** Federal Grants (as PI or Co-I)
NIDA (R01 DA025659), "REALTIME waterpipe tobacco smoke toxicant sampling in the natural environment." Start date: December, 2010. Duration: 5 years. Direct costs: \$1,330,000. Co-Principal Investigator (with Dr. Alan Shihadeh).
NCI (R01 CA140150), "Waterpipe tobacco smoking among U.S. adolescents and young adults." Start date: May, 2010. Duration: 5 years. Direct costs: \$2,000,000. Co-Investigator.
NCI (R01 CA120142), "Waterpipe tobacco smoke: toxicant exposure and effects." Start date: February, 2008. Duration: 5 years. Direct costs: \$2,307,038. Principal Investigator.
FIC (R03 TW008371), "Waterpipe tobacco smoking: trends, toxicants, and capacity building in Jordan." Start date: September, 2009. Duration: 3 years. Direct costs: \$150,000. Principal Investigator.
NIDA (R03 DA027619), "Variants in nicotine receptors and pharmacogenetics." Start date: September 1, 2009. Duration: 3 years. Direct costs: \$440,000. Co-investigator.

NIDA (R13 DA016409), “Society for Research on Nicotine and Tobacco Annual Meeting.”
Start date: January, 2008. Duration: 5 years. Direct costs: \$404,707. Principal Investigator.

NIDA (R01 DA024876), “Responding to the changing tobacco epidemic in the Eastern Mediterranean Region.” Start date: July, 2008. Duration: 5 years. Direct costs: \$1,575,950. Co-Investigator.

NCI (R01 CA103827), “Clinical models for evaluating PREPs for tobacco users.” Start date: February, 2004. Duration: 5 years. Direct costs: \$1,455,400. Principal Investigator.

NIDA (R01 DA11082), “Drug craving: pharmacologic and associative influences.” Start date: July, 2002. Duration: 5 years. Direct costs: \$1,250,000. Principal Investigator.

FIC (R01 TW005962), “Establishment of the Syrian Center for Tobacco Studies.” Start date: July, 2002. Duration: 5 years. Direct costs: \$1,187,767. Co-Investigator.

NIDA (R29 DA11082), “Drug craving: pharmacologic and associative influences.” Start date: July, 1997. Duration: 5 years. Direct costs: \$349,000. Principal Investigator.

NIDA (P50 DA05274 10S1), “Center for drug abuse research (supplement)”. Start date: August 1, 1999. Duration: 3 years. Direct costs: \$210,238. Component Principal Investigator.

Federal Grants (as National Service Research Award Sponsor)

NIDA, (F31 DA028102), “Evaluating the acute effects of caffeinated waterpipe tobacco” (C. Cobb, PI). Start date: February, 2010. Duration: 2 years.

NIDA, (F31 DA018447), “Does puff topography measurement alter smoking behavior?” (M. Blank, PI). Start date: September, 2004. Duration: 3 years.

NIDA, (F31 DA017437), “Tobacco abstinence-induced cognitive decrements.” (B. A. Kleykamp, PI). Start date: September, 2003. Duration: 4 years.

NIDA, (F31 DA015570), “Evaluating Risk Reduction Products for Smokers.” (A. Breland, PI). Start date: August, 2002. Duration: 3 years.

NIDA, (F31 DA006052), “Gender and Nicotine Withdrawal – A Placebo Control Study.” (A.R. Buchhalter, PI). Start date: August, 2000. Duration: 2 years.

Industry Grants/Contracts

Sention, Inc. “A Randomized, Double-blind, Placebo-Controlled, Crossover Study Comparing C105 to *dextro*-Amphetamine Sulfate and Placebo in Healthy, Non-Dependent Stimulant Abuser Subjects. Start date: June 2001. Duration: 6 months. Direct costs: (b) (6). Principal Investigator.

Plowshare Technologies, Inc., “Comparison of Two Smoking Measurement Systems”. Start date: June 1, 2001. Duration: 5 months. Direct costs: (b) (6). Principal Investigator.

Purdue Pharma L.P., “A randomized, double-blind study of the effects of oral naltrexone on analgesia induced by 15 mg immediate-release oral hydrocodone”. Start date: October 1, 1999. Duration: 5 months. Direct costs: (b) (6). Principal Investigator.

Adolor Corporation, “The initial, phase 1 ascending dose evaluation of the safety, tolerance, and antihyperalgesic properties of ADL 10-0101”. Start date: May 5, 1999. Duration: 5 months. Direct costs: (b) (6). Principal Investigator.

Eli Lilly and Company, “Neuroleptics in schizophrenic outpatient smokers: the effects of olanzapine and risperidone on smoking behavior.” Start date: April 1, 1999. Duration: 1.5 years. Direct costs: (b) (6). Co-Investigator.

Adolor Corporation, “The effects of an opioid antagonist on opioid-induced analgesia.” Start Date: November 1, 1998. Duration: 6 months. Direct costs: (b) (6) Principal Investigator.

Adolor Corporation, “Analgesia with a topical opioid.” Start date: July 25, 1998. Duration: 4 months. Direct costs: (b) (6). Principal Investigator.

Adolor Corporation, “Analgesia demonstration project.” Start date: April 14, 1998. Duration: 3 months. Direct costs: (b) (6). Principal Investigator.

Foundation and Other Grants

- Virginia Tobacco Settlement Foundation, “Virginia Youth Tobacco Dependence Prevention Center”. Start date: March, 2002. Duration: 3 years. Direct costs: (b) (6). Co-Investigator.
- Massey Cancer Center Pilot Project Program, “Clinical Model for Evaluating Tobacco Harm Reduction”. Duration: 1 year. Direct costs: (b) (6). Co-Principal Investigator.
- Robert Wood Johnson Foundation Tobacco Etiology Research Network Faculty Scholars Program. Duration: 3 years. Direct costs: (b) (6). Principal Investigator.

Awards

- Joseph Cochin Young Investigator Award, College on Problems of Drug Dependence, 2005
- VCU’s College of Humanities and Sciences Excellence in Scholarship Award, 2002.
- Robert Wood Johnson Foundation Tobacco Etiology Research Network Faculty Scholars Program Faculty Scholar, January 1, 2000 – December 31, 2004.
- NIDA Travel Award for Junior Investigators in the Field of Women, Gender, and Drug Abuse, 1999.
- American Psychological Association, Division 28, Wyeth-Ayerst Young Psychopharmacologist Award, 1998.
- College on Problems of Drug Dependence Travel Award, 1997.
- National Institute on Drug Abuse Director's Travel Award, 1995.
- Ontario Graduate Scholarship, 1992-93.
- Clifton W. Sherman Scholarship, McMaster University, 1991-92.
- McMaster Psychology Departmental Scholarship, 1989-90, 1990-91.

Publications

1. Blank, M.D., Nasim, A., Hart Jr., A., & Eissenberg, T. (in press). Acute effects of cigarillo smoking. *Nicotine & Tobacco Research*.
2. Lipkus, I., Eissenberg, T., Schwartz-Bloom, R.D., Prokhorov, A.V., & Levy, J. (in press). Affecting perceptions of harm and addiction among college waterpipe tobacco smokers. *Nicotine & Tobacco Research*.
3. Cobb, C.O., Weaver, M.F., Shihadeh, A., & Eissenberg, T. (2011). Waterpipe tobacco smoking and cigarette smoking: a direct comparison of toxicant exposure and subjective effects. *Nicotine & Tobacco Research*, 13, 78-87
4. Etter, J-F., Bullen, C., Flouris, A., Laugesen, M., & Eissenberg T. (2011). Electronic nicotine delivery systems : a research agenda. *Tobacco Control*.
5. Rastam, S., Eissenberg, T., Ibrahim, I., Ward, K.D., Khalil, R., & Maziak, W. (2011). Comparative analysis of waterpipe and cigarette suppression of abstinence and craving symptoms. *Addictive Behaviors*, 36, 555-9
6. Blank, M.D., Cobb, C.O., Kilgaleen, B., Austin, J., Weaver, M.F., Shihadeh, A., & Eissenberg, T. (2011). Acute effects of waterpipe tobacco smoking: a double-blind, placebo-control study. *Drug and Alcohol Dependence*.
7. Kleykamp, B.A., Jennings, J.M., & Eissenberg, T.E. (2011). Effects of transdermal nicotine and concurrent smoking on cognitive performance in tobacco-abstinent smokers. *Experimental and Clinical Psychopharmacology*, 19, 75-84.
8. Blank, M.D., & Eissenberg, T. (2010). Evaluating oral, non-combustible potential reduced exposure products for smokers. *Nicotine & Tobacco Research*, 12, 336-343.

9. Maziak, W., Rastam, S., Shihadeh, A.L., Bazzi, A., Ibrahim, I., Zaatari, G.S., Ward, K.D., & Eissenberg, T. (2010). Nicotine exposure in daily waterpipe smokers and its relation to puff topography. *Addictive Behaviors*, 36, 397-9.
10. Vansickel, A.R., Cobb, C.O., Weaver, M.F., & Eissenberg, T. (2010). A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. *Cancer Epidemiology, Biomarkers & Prevention*, 19, 1945-53.
11. Azab, M., Khabour, O.F., Alkaraki, A.K., Eissenberg, T., AlZoubi, K.H., Primack, B.A. (2010). Waterpipe Tobacco Smoking Among University Students in Jordan. *Nicotine & Tobacco Research*, 12, 606-12.
12. England, L.J., Kim, S.Y., Tomar, S., Ray, C., Gupta, P.C., Eissenberg, T., Cnattingius, S., J.T., Bernert, Tita, A.T.N., Winn, D., Djordjevic, M., Lambe, M., Stamilo, D., Chipato, T., & Tolosa J.E. (2010). Non-cigarette tobacco use among women and adverse pregnancy outcomes. *Acta Obstetrica et Gynecologica Scandinavica*, 89, 454-64.
13. Cobb, C., Weaver, M.F., & Eissenberg, T. (2010). Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers. *Tobacco Control*, 19, 367-73.
14. Eissenberg, T. (2010). Electronic “cigarettes”: ineffective nicotine delivery and craving suppression after acute administration. *Tobacco Control*, 19, 87-88.
15. Cobb, C., Ward, K.D., Maziak W., Shihadeh A.L., & Eissenberg T. (2010). Waterpipe tobacco smoking: an emerging health crisis in the United States. *American Journal of Health Behavior*, 34, 275-285.
16. Maziak W., Rastam, S., Ibrahim, I., Ward, K.D., Shihadeh, A., & Eissenberg, T. (2009). CO exposure, puff topography, and subjective effects in waterpipe tobacco smokers. *Nicotine & Tobacco Research*, 11, 806-11.
17. Eissenberg, T. & Shihadeh, A. (2009). Waterpipe tobacco and cigarette smoking: direct comparison of toxicant exposure. *American Journal of Preventive Medicine*, 37, 518-523.
18. Cohen, J.E., Zeller, M., Eissenberg, T., Parascandola, M., O’Keefe, R., Planinac, L., & Leischow, S. (2009). Criteria for evaluating tobacco control research funding programs and their application to models that include financial support from the tobacco industry. *Tobacco Control*, 18, 228-34.
19. Zeller, M., Hatsukami, D., Backinger, C., Benowitz, N., Biener, L., Burns, D., Clark, P., Connolly, G., Djordjevic, M.V., Eissenberg, T., Giovino, G.A., Heaton, C., Hecht, S.S., Henningfield, J.E., Husten, C., Kobus, K., Leischow, S., Levy, D.T., Marcus, S., Myers, M.L., Parascandola, M., Pankshel, P., Shields, P.G., Slovic, P., Swenor, D., & Warner, K.E. (2009). The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the United States. *Tobacco Control*, 18, 324-32.
20. Blank, M.D., Disharoon, S. & Eissenberg T. (2009). Comparison of methods for measurement of smoking behavior: mouthpiece-based computerized devices versus direct observation. *Nicotine & Tobacco Research*, 11, 896-903.
21. Primack, B.A., Walsh M., Bryce, C., & Eissenberg, T. (2009). Waterpipe tobacco smoking among middle and high school students in Arizona. *Pediatrics*, 123, e282-8.

22. Primack, B.A., Sidani, J., Agarwal, A., Shadel, W., Donny, E., & Eissenberg, T. (2008). Prevalence of and associations with waterpipe tobacco smoking among college students. *Annals of Behavioral Medicine*, 36, 81-86.
23. Gray, J.N., Breland, A.B., Weaver, M.F., & Eissenberg, T. (2008). Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology. *Nicotine & Tobacco Research*, 10, 1441-1448.
24. Abrams, K., Zvolensky M., Dorflinger, L., Galatis, A., Blank, M., & Eissenberg, T. (2008). Fear reactivity to bodily sensations among heavy smokers and non-smokers. *Experimental and Clinical Psychopharmacology*, 16, 230-239.
25. Kleykamp, B.A., Jennings, J.M., Sams, C., Weaver M.F., & Eissenberg, T. (2008). The influence of transdermal nicotine on tobacco/nicotine abstinence and the effects of a concurrently administered cigarette in women and men. *Experimental and Clinical Psychopharmacology*, 16, 99-112.
26. Hammal, F., Mock, J., Ward, K.D., Eissenberg, T., & Maziak, W. (2008). A pleasure among friends: how narghile (waterpipe) smoking differs from cigarette smoking in Syria. *Tobacco Control*, 17, e3.
27. Blank, M.D., Sams, C., Weaver M.F., & Eissenberg, T. (2008). Nicotine delivery, cardiovascular profile, and subjective effects of an oral tobacco product for smokers. *Nicotine & Tobacco Research*, 10, 417-421.
28. Maziak, W., Rastam, S., Ibrahim, I., Ward, K.D., & Eissenberg, T. (2008). Waterpipe Associated Particulate Matter Emissions. *Nicotine & Tobacco Research*, 10, 519-523.
29. Smith-Simone, S.Y., Maziak, W., Ward, K.D., & Eissenberg, T. (2008). Waterpipe Tobacco Smoking: Knowledge, Attitudes, Beliefs, and Behavior in Two U.S. Samples. *Nicotine & Tobacco Research*, 10, 393-398.
30. Eissenberg, T., Ward, K.D., Smith-Simone, S., & Maziak, W. (2008). Waterpipe tobacco smoking on a U.S. college campus: prevalence and correlates. *Journal of Adolescent Health*, 10, 526-529.
31. Asfar, T., Vander Weg, M., Maziak, W., Hammal, F., Eissenberg, T., & Ward, K.D. (2008). Outcomes and adherence in Syria's first smoking cessation trial. *American Journal of Health Behavior*, 32, 146-156.
32. Maziak, W., Al Ali, R., Fouad, M.F., Rastam, S., Wipfli, H., Travers, M.J., Ward, K.D., & Eissenberg, T. (2008). Exposure to secondhand smoke at home and in public places in Syria: a developing country's perspective. *Inhalation Toxicology*, 20, 17-24.
33. Acosta, M.C., Eissenberg, T., Nichter, M., Nichter, M., Balster, R.L., & Tobacco Etiology Research Network (TERN). (2008). Characterizing Early Cigarette Use Episodes in Novice Smokers. *Addictive Behaviors*, 33, 106-121.
34. Maziak, W., Ward, K.D., Eissenberg, T. (2007). Interventions for waterpipe smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD005549. DOI: 10.1002/14651858.CD005549.pub2.

35. Maziak, W., Rastam, S., Mzayek, F., Ward, K.D., Eissenberg, T., & Keil, U. (2007). Cardiovascular health among adults in Syria: a model from developing countries. *Annals of Epidemiology*, *17*, 713-20
36. Ward, K.D., Eissenberg, T., Gray, J., Srinivas, V., Wilson, N., & Maziak, W. (2007). Characteristics of American waterpipe users: a preliminary report. *Nicotine & Tobacco Research*, *9*, 1339-1346.
37. Blank, M., Kleykamp B.A., Jennings, J.M., & Eissenberg, T. (2007). Caffeine's influence on nicotine's effects in non-smokers. *American Journal of Health Behavior*, *31*, 473-483.
38. Kassel, J.D., Greenstein, J.E., Evatt, D.P., Wardle, M.C., Yates, M.C., Veilleux, J.C., & Eissenberg, T. (2007). Smoking topography in response to denicotinized and high-yield nicotine cigarettes in adolescent smokers. *Journal of Adolescent Health*, *40*, 54-60.
39. Breland, A.B., Kleykamp, B.A., & Eissenberg, T. (2006). Clinical laboratory evaluation of potential reduced exposure products for smokers. *Nicotine & Tobacco Research*, *8*, 727-738.
40. Maziak, W., Ward, K.D., & Eissenberg, T. (2006). Measuring exposure to environmental tobacco smoke (ETS): a developing country's perspective. *Preventive Medicine*, *42*, 409-14.
41. Ward, K.D., Eissenberg, T., Rastam, S., Asfar, T., Mzayek, F., Fouad, M.F., Hammal, F., Mock, J., & Maziak, W. (2006). The tobacco epidemic in Syria. *Tobacco Control*, *15*, 24-29.
42. Evans, S.E., Blank, M., Sams, C., Weaver, M.F., & Eissenberg, T. (2006). Transdermal-nicotine induced tobacco abstinence symptom suppression: nicotine dose and smokers' gender. *Experimental and Clinical Psychopharmacology*, *14*, 121-35.
43. Eissenberg, T. (2006). The time for tobacco industry-sponsored PREP evaluation has arrived. *Tobacco Control*, *15*, 1-2.
44. Shihadeh, A. & Eissenberg, T. (2005). Tobacco smoking using a waterpipe: product, prevalence, chemistry/toxicology, pharmacological effects, and health hazards. *Waterpipe tobacco smoking – Building the Evidence Base. Part 1: The smoke Chemistry*. RITC Monograph Series No. 2. International Development Research Center, Ottawa, Canada.
45. Kleykamp, B.A., Jennings, J.M., Blank, M., & Eissenberg, T. (2005). The effects of nicotine on attention and working memory in never-smokers. *Psychology of Addictive Behaviors*, *19*, 433-438.
46. Hatsukami, D.K., Giovino, G.A., Eissenberg, T., Clark, P.I., Lawrence, D. & Leischow, S. (2005). Methods to Assess Potential Reduced Exposure Products. *Nicotine & Tobacco Research*, *7*, 827-44.
47. Maziak W., Ward K.D., & Eissenberg, T. (2005). Interventions for waterpipe smoking cessation (protocol). *The Cochrane Database of Systematic Reviews*, Issue 4. Art. No.: CD005549.
48. Buchhalter, A.R., Acosta, M.C., Evans, S.E., Breland, A.B., & Eissenberg, T. (2005). Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. *Addiction*, *100*, 550-559.

49. Maziak, W., Ward, K.D., Afifi Soweid, R.A., & Eissenberg, T. (2005). Standardizing questionnaire items for the assessment of waterpipe use in epidemiological studies. *BMC Public Health*, *119*, 400-404.
50. Ward, K.D., Hammal, F., Vander Weg, M.W., Maziak W., Eissenberg, T., Asfar, T., & Rastam, S. (2005). Are waterpipe users interested in quitting? *Nicotine & Tobacco Research*, *7*, 149-156.
51. Asfar, T., Ward, K.D., Eissenberg, T., & Maziak, W. (2005). Comparison of patterns of use, beliefs, and attitudes related to waterpipe between beginning and established smokers. *BMC Public Health*, *5*, 19.
52. Maziak, W., Ward, K.D., Rastam, S., Mzayek F., & Eissenberg, T. (2005). Extent of exposure to environmental tobacco smoke (ETS) and its dose-response relation to respiratory health among adults. *Respiratory Research*, *6*, 13.
53. Maziak, W., Eissenberg, T., & Ward, K.D. (2005). Waterpipe use and dependence: implications for intervention development. *Pharmacology, Biochemistry, and Behavior*, *80*, 173-179.
54. Acosta, M.C., Buchhalter, A.R., Breland, A.B., Hamilton, D.C.P., & Eissenberg, T. (2004). Urine Cotinine as an Index of Smoking Status in Abstinent Smokers: Comparison of GC/MS with Immunoassay Test Strip. *Nicotine & Tobacco Research*, *6*, 615-620.
55. Maziak, W., Eissenberg, T., Rastam, S., Hammal, F., Asfar, T., Bachir, M.E., Fouad, M.F., & Ward, K.D. (2004). Beliefs and attitudes related to narghile (waterpipe) smoking among university students in Syria. *Annals of Epidemiology*, *14*, 646-54.
56. Eissenberg, T., Paniker, S., Berenbaum, S., Epley, N., Fendrich, M., Kelso, R., Penner, L., Simmerling, M., (2004). IRBs and Psychological Science: Ensuring a Collaborative Relationship. Available online at http://www.apa.org/science/rcr/irbs_psychsci.html.
57. Maziak, W., Ward, K.D., Afifi Soweid, R.A., & Eissenberg, T. (2004). Tobacco smoking using a waterpipe: a re-emerging strain in a global epidemic. *Tobacco Control*, *13*, 327-333.
58. Rastam S., Ward, K.D., Eissenberg, T., & Maziak, W. (2004). Estimating the beginning of the waterpipe epidemic in Syria. *BMC Public Health*, *4*, 32.
59. Maziak, W., Rastam, S., Asfar, T., Hammal, F., Eissenberg, T., Bachir, M.E., Fouad, M.F., & Ward, K.D. (2004). Characteristics of cigarette smoking and quitting among university students in Syria. *Preventive Medicine*, *39*, 330-336.
60. Maziak, W., Fouad, M.F., Asfar, T., Hammal, F., Bachir, M.E., Rastam, S., & Eissenberg, T., Ward, K.D. (2004). Prevalence and characteristics of narghile smoking among university students in Aleppo, Syria. *International Journal of Tuberculosis and Lung Disease*, *8*, 882-889.
61. Maziak, W., Ward, K.D., & Eissenberg, T., Klesges, R.C., and Keil, U. (2004). The Syrian Center for Tobacco Studies: a model of international partnership for the creation of a sustainable research basis in developing countries. *Promotion and Education*, *11*, 29-33.

62. Maziak, W., Ward, K.D., & Eissenberg, T. (2004). Factors related to frequency of narghile (waterpipe) use: the first insights on tobacco dependence in narghile users. *Drug and Alcohol Dependence*, 76, 101-106.
63. Maziak, W., Rastam, S., Eissenberg, T., Asfar, T., Hammal, F., Bachir, M.E., Fouad, M.F., & Ward, K.D. (2004). Gender and smoking status-based analysis of views regarding waterpipe and cigarette smoking in Aleppo, Syria. *Preventive Medicine*, 38, 479-484.
64. Eissenberg, T. (2004). Measuring the emergence of tobacco dependence: the contribution of negative reinforcement models. *Addiction*, 99 (Suppl 1), 5-29.
65. Maziak, W., Eissenberg, T., Klesges, R.C., Kiel, U., & Ward, K.D. (2004). Adapting smoking cessation interventions for developing countries: a model for the middle east. *International Journal of Tuberculosis and Lung Disease*, 8, 403-413.
66. Breland, A.B., Acosta M.C., & Eissenberg, T. (2003). Tobacco-specific nitrosamines and potential reduced exposure products for smokers: a preliminary evaluation of Advance™. *Tobacco Control*, 12, 317-321.
67. Klein, L.C. & Eissenberg, T. (2003). Recent advances in nicotine and tobacco research. *Nicotine & Tobacco Research*, 5, 761-794.
68. Eissenberg, T. (2003). Teaching successful grant writing to psychology graduate students. *Teaching of Psychology*, 30, 328-330.
69. Walsh, S.L. & Eissenberg, T. (2003). The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. *Drug and Alcohol Dependence*, 70 (2 Suppl), S13-27.
70. Breland, A.B., Evans, S.E., Buchhalter, A.R., & Eissenberg, T. (2002). Acute effects of Advance™: a potential reduced exposure product for smokers. *Tobacco Control*, 11, 376-378.
71. Breland, A.B., Buchhalter, A.R., Evans, S.E., & Eissenberg, T. (2002). Evaluating acute effects of potential reduced exposure products for smokers: clinical laboratory methodology. *Nicotine & Tobacco Research*, 4 (Suppl 2), S131-S140.
72. Eissenberg, T. (2002). Progress in nicotine and tobacco research. *Nicotine & Tobacco Research*, 4, 355-362.
73. Donny, E.C., Walsh, S.L., Bigelow, G.E., Eissenberg, T., & Stitzer M.L. (2002). Low-to-moderate methadone doses suppress withdrawal, but fail to block heroin's effects completely. *Psychopharmacology*, 161, 202-212.
74. Houtsmuller, E.J., Fant, R.V., Eissenberg, T., Henningfield, J.E., & Stitzer M.L. (2002). Flavor improvement does not increase abuse liability of nicotine chewing gum. *Pharmacology, Biochemistry, and Behavior*, 72, 559-568.
75. Corrigan, W.A., Zack, M., Eissenberg, T., Belsito, L., & Scher, R. (2001). Acute subjective and physiological responses to smoking in adolescents. *Addiction*, 96, 1409-1417.
76. Buchhalter A.R., Schrinel, L., & Eissenberg, T. (2001). Withdrawal suppressing effects of a novel smoking system: comparison with own brand, not own brand, and denicotinized cigarettes. *Nicotine & Tobacco Research*, 3, 111-118.

77. Zack, M., Belsito, L., Scher, R., Eissenberg, T., & Corrigan, W.A. (2001). Effects of abstinence and smoking on information processing in adolescent smokers. *Psychopharmacology*, *153*, 249-257.
78. Gire, J.T. & Eissenberg, T. (2000). Placebo control study of acute smokeless tobacco abstinence in young adult men. *Psychology of Addictive Behaviors*, *14*, 356-366.
79. Eissenberg, T., & Balster, R.L. (2000). Initial tobacco use episodes in adolescents: current knowledge, future directions. *Drug and Alcohol Dependence*, *59* (Suppl 1), S41-S60.
80. Buchhalter A.R. & Eissenberg, T. (2000). Preliminary evaluation of a novel smoking system: effects on subjective and physiological measures and on smoking behavior. *Nicotine & Tobacco Research*, *2*, 39-43.
81. Eissenberg, T., Riggins, E.C.R. III, Harkins, S.W., & Weaver, M.F. (2000). A clinical laboratory model for direct assessment of medication-induced antihyperalgesia and subjective effects: initial validation studies. *Experimental and Clinical Psychopharmacology*, *8*, 47-60.
82. McCaul, M.E., Wand, G.S., Eissenberg, T., Rohde, C.A., & Cheskin, L.J. (2000). Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. *Neuropsychopharmacology*, *22*, 480-492.
83. Eissenberg, T., Adams, C., Riggins, E.C.R. III, & Likness, M. (1999). Smokers' sex and the effects of tobacco cigarettes: subject-rated and physiological measures. *Nicotine & Tobacco Research*, *1*, 317-324.
84. Eissenberg, T., Stitzer, M.L., Bigelow, G.E., Buchhalter, A.R., & Walsh, S.L. (1999). Relative potency of levo-alpha acetylmethadol and methadone in humans under acute dosing conditions. *Journal of Pharmacology and Experimental Therapeutics*, *289*, 936-946.
85. Eissenberg, T., Stitzer, M.L., & Henningfield, J.E. (1999). Current issues in nicotine replacement. In: *Helping the Hard-core Smoker: a Clinician's Guide*, D.F. Seidman and L.S. Covey (Eds), Lawrence Erlbaum Associates, Mahwah, NJ. pp 137-158.
86. Jones, H.E., Strain, E.C., Bigelow, G.E., Walsh, S.L., Stitzer, M.L., Eissenberg, T., & Johnson, R.E. (1998). Induction with levomethadyl acetate: safety and efficacy. *Archives of General Psychiatry*, *55*, 729-736.
87. Allan, L.G., Siegel, S., Eissenberg, T., & Thomas S.E. (1998). More on the associative interpretation of the indirect McCollough Effect. *Quarterly Journal of Experimental Psychology*, *50*, 332-349.
88. Eissenberg, T., Bigelow, G.E., Strain, E.C., Walsh, S.L., Brooner, R.K., Stitzer, M.L., & Johnson, R.E. (1997). Dose related efficacy of levomethadyl acetate for treatment of opioid dependence: a randomized clinical trial. *Journal of the American Medical Association*, *277*, 1945-1951.
89. Eissenberg, T., Johnson, R.E., Strain, E.C., Liebson, I.A., Bigelow, G.E., Walsh, S.L., & Stitzer, M.L. (1997) Controlled opioid withdrawal evaluation during 72-hour dose omission in buprenorphine-maintained patients. *Drug and Alcohol Dependence*, *45*, 81-91.
90. Eissenberg, T. & Griffiths, R.R. (1997). Human drug discrimination and multiple chemical sensitivity: caffeine exposure as an experimental model. *Environmental Health Perspectives*, *105* (Suppl 2), 509-513.

91. Allan, L.G., Siegel, S., Kulatunga-Moruzi C., Eissenberg, T., & Chapman, C.A. (1997). Isoluminance and contingent color aftereffects. *Perception and Psychophysics*, 59, 1327-1334.
92. Eissenberg, T., Griffiths, R.R., & Stitzer M.L. (1996). Mecamylamine does not precipitate withdrawal in cigarette smokers. *Psychopharmacology*, 127, 328-336.
93. Eissenberg, T., Greenwald, M.K., Johnson, R.E., Liebson, I.A., Bigelow, G.E., & Stitzer, M.L. (1996). Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. *Journal of Pharmacology and Experimental Therapeutics*, 276, 449-459.
94. Eissenberg, T., Allan, L.G., Siegel, S., & Petrov, N. (1995). An associative interpretation of the indirect McCollough effect. *Quarterly Journal of Experimental Psychology*, 48B, 262-286.
95. Johnson, R.E., Eissenberg, T., Stitzer, M.L., Strain, E.C., Liebson, I.A., & Bigelow, G.E. (1995). Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. *Drug and Alcohol Dependence*, 40, 27-35.
96. Johnson, R.E., Eissenberg, T., Stitzer, M.L., Strain, E.C., Liebson, I.A., & Bigelow, G.E. (1995). A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. *Drug and Alcohol Dependence*, 40, 17-25.
97. Siegel, S., Allan, L.G., & Eissenberg, T. (1994). Scanning and form-contingent color aftereffects. *Journal of Experimental Psychology: General*, 123, 91-94.
98. Eissenberg, T., Allan, L.G., & Siegel, S. (1992). How indirect is the "indirect" McCollough Effect? In G. Borg and G. Neeley (Eds.), *Proceedings of the 8th Annual Meeting of the International Society for Psychophysics*. (pp 249-254). Stockholm: Stockholm University Press.
99. Siegel, S., Allan, L.G., & Eissenberg, T. (1992). The associative basis of contingent color aftereffects. *Journal of Experimental Psychology: General*, 121, 79-94.
100. Tipper, S.P., Eissenberg, T., & Weaver, B. (1992). The effects of practice on mechanisms of attention. *Bulletin of the Psychonomic Society*, 30, 77-80.
101. Connelly, F.W., Eissenberg, T.E., & Hunt, N.L. (1991). The Consensor classroom and knowledge retention. *Educational Technology*, 31, 51-5.
102. Siegel, S., Allan, L.G., Roberts, L., & Eissenberg, T. (1990). Effect of spatial contingency on the McCollough effect. *Perception and Psychophysics*, 48, 307-312.
103. Connolly, F. & Eissenberg, T. (1990). The feedback classroom: Teaching's silent friend. *Technological Horizons in Education Journal*, 17, 75-77.
104. Rudner, L.M. & Eissenberg, T. (1989). Standard-setting practices for teacher tests. *Journal of Personnel Evaluation in Education*, 3, 143-149.
105. Eissenberg, T. & Rudner, L.M. (1988). State testing of teachers: A summary. *Journal of Teacher Education*. 39, 21-22.
106. Eissenberg, T. & Rudner, L.M. (1988). Explaining test results to parents. *Practical Assessment*, 1.

- Presentations**
1. Eissenberg, T., Vansickel, A.R., Cobb, C.O., Blank, M., Kilgalen, B., Austin, J., Weaver, M.F. (2010, April). Acute effects of electronic cigarettes. Poster presented to the 16th Annual Meeting of the Society for Research on Nicotine and Tobacco, Baltimore, Maryland.
 2. Cobb, C., Eissenberg, T., Shihadeh, A., Kilgalen, B., Austin, J., Blank, M.D., & Weaver, M.F. (2010, April). Waterpipe tobacco smoking and cigarette smoking: a direct comparison of subjective effects. Poster presented to the 16th Annual Meeting of the Society for Research on Nicotine and Tobacco, Baltimore, Maryland.
 3. Eissenberg, T., Blank, M.D., Shihadeh, A., Kilgalen, B., Austin, J., Cobb, C., & Weaver, M.F. (2010, April). Acute effects of waterpipe tobacco smoke: a double-blind, placebo control study. Poster presented to the 16th Annual Meeting of the Society for Research on Nicotine and Tobacco, Baltimore, Maryland.
 4. Cohen, J., Zeller, M., Eissenberg, T., O’Keefe, R., Leischow, S., Parascandola, M., Planinac, L. (2009, March). Criteria for Evaluating Tobacco Control Research Funding Programs and their Application to Models that Include Financial Support from the Tobacco Industry. Poster presented at the 14th World Conference on Tobacco Or Health, Mumbai, India.
 5. Kilzieh, N., Rastam, S., Maziak, W., Tapp, A., Eissenberg, T. (2009, September). Negative Affect in Depressed vs. Non-Depressed Smokers after Brief Nicotine Abstinence. Poster presented to the 22nd European Congress of Neuropsychopharmacology Congress, Istanbul, Turkey.
 6. Eissenberg, T. (2009, April). Waterpipe Tobacco Smoking: A Re-emerging Strain in the Tobacco Epidemic? In: Global tobacco research and testing: understanding the changing threat. The WHO Tobacco Free Initiative. Preconference symposium to the 15th Annual Meeting of the Society for Research on Nicotine and Tobacco, Dublin, Ireland.
 7. Eissenberg, T., Shihadeh, A., Kilgalen, B., Austin, J., Cobb, C., Bagley, J., Blank, M.D., Weaver, M.F. (2009, April). Waterpipe tobacco smoking and cigarette smoking: a direct comparison of toxicant exposure. Poster presented to the 15th Annual Meeting of the Society for Research on Nicotine and Tobacco, Dublin, Ireland.
 8. Al Ali, R., Rastam, S., Maziak, M., Eissenberg, T., & Ward, K.D. (2009, April). Effects of cigarette and waterpipe smoking on overweight and obesity: results from the two population-based surveys in Aleppo, Syria. Poster presented to the 15th Annual Meeting of the Society for Research on Nicotine and Tobacco, Dublin, Ireland.
 9. Eissenberg, T. (2008, February). Evaluating oral, non-combustible potential reduced exposure products for smokers. Paper presented at the 14th Annual Meeting of the Society for Research on Nicotine and Tobacco, Portland, OR.
 10. Eissenberg, T (2008, November). *Balancing Ethics and Regulations in the Social and Behavioral Research Setting: Science-Based IRB Policy*. Paper presented to the Advancing Ethical Research Conference of the Public Responsibility in Medicine and Research, Orlando, FL.
 11. Eissenberg, T. (2008, November). *What Can Science Tell Us About Hookah Smoking?* Invited Address to the Health Outreach Peer Educator group at the College of William and Mary, Williamsburg, VA.

12. Eissenberg, T. (2008, September). *Research models for evaluating potential reduced exposure products for tobacco users*. Invited address to the 10th Annual Meeting of the Society for Research on Nicotine and Tobacco: Europe, Rome, Italy.
13. Eissenberg, T. (2008, August). *Establishing a Collaborative IRB-Researcher Relationship: Role of the IRB member*. Paper presented to the Annual Meeting of the American Psychological Association, Boston, MA.
14. Eissenberg, T. (2008). *Using a Waterpipe to Smoke Tobacco: Prevalence, Toxicant Exposure, Effects, and Research Needs*. Paper presented to the Annual Meeting of the American Psychological Association, Boston, MA.
15. Eissenberg, T. (2008, July). *Understanding the Effects of Tobacco Use: Role of the Clinical Behavioral Pharmacology Laboratory*. Paper presented at The First Syrian Center for Tobacco Studies International Summer Program for Tobacco Control Research, Aleppo, Syria.
16. Eissenberg, T. (2008, July). *Introduction to Grantwriting*. Paper presented at The First Syrian Center for Tobacco Studies International Summer Program for Tobacco Control Research, Aleppo, Syria.
17. Primack, B.A., Sidani, J., Agarwal, A.A., Shadel, W.S., Donny, E.C., & Eissenberg, T.E. (2008, March). *Prevalence of and associations with waterpipe tobacco smoking among U.S. university students*. Poster presentation at the annual meeting of the Society for Adolescent Medicine. Greensboro, NC.
18. Eissenberg, T. (2008, March). *Some facts about hookah smoking*. Presentation to “Brain Day” a program for gifted Richmond-area high school students.
19. Cobb, C., Ward, K.D., Maziak, W., & Eissenberg, T. (2008, February). *Increases in waterpipe tobacco smoking prevalence on a U.S. college campus*. Poster presented at the 14th Annual Meeting of the Society for Research on Nicotine and Tobacco, Portland, OR.
20. Cobb, C.O., Austin, J., Kilgalen, B. & Eissenberg, T. (2008, February). *Evaluating the acute effects of oral, non-combustible potential reduced exposure products for smokers: a preliminary report*. Poster presented at the 14th Annual Meeting of the Society for Research on Nicotine and Tobacco, Portland, OR.
21. Maziak, W., Al Ali, R., Fouad, M.F., Rastam, S., Travers, M., Ward, K.D., & Eissenberg, T. (2008, February). *Exposure to secondhand smoke at home and in public places in Syria: a developing country’s perspective*. Poster presented at the 14th Annual Meeting of the Society for Research on Nicotine and Tobacco, Portland, OR.
22. Hammal, F., Ward, K.D., Fouad, M.F., Eissenberg, T., & Maziak, W. (2008, February). *Dependence features among waterpipe users*. Poster presented at the 14th Annual Meeting of the Society for Research on Nicotine and Tobacco, Portland, OR.
23. Asfar, T., Ward, K.D., Al Ali, R., Vander Weg, M.W., Eissenberg, T., & Maziak, W. (2008, February). *Increases in waterpipe tobacco smoking prevalence on a U.S. college campus*. Poster presented at the 14th Annual Meeting of the Society for Research on Nicotine and Tobacco, Portland, OR.
24. Eissenberg, T. (2007, August). *Psychologists and IRBs: Working Collaboratively to Protect Research Participants*. Paper presented to the Annual Meeting of the American Psychological Association, San Francisco, CA.

25. Eissenberg, T. (2007, February). *Using a waterpipe to smoke tobacco: prevalence, toxicant exposure, effects, and research needs*. Paper presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
26. Eissenberg, T. (2007, October). Exposure Reduction, Harm Reduction, and Tobacco Control. Invited address to the 9th Annual Meeting of the Society for Research on Nicotine and Tobacco: Europe, Madrid, Spain.
27. Kleykamp, B., Jennings, J., Sams, C., Shaffer, D., Austin, J., Gray, J., Weaver, M., & Eissenberg, T. (2007, February). *The effects of smoking-related stimuli on cognitive performance*. Paper presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
28. Sams, C., Blank, M.D., Weaver, M.F., & Eissenberg, T. (2007, February). *The nicotine delivery, cardiovascular profile, and subjective effects of an oral tobacco product for smokers*. Poster presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
29. Ward, K.D., Eissenberg, T., Gray, J., Srinivas, V., Wilson, N., Smith-Simone, S., & Maziak, W. (2007, February). *Characteristics of American waterpipe users: a preliminary report*. Poster presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
30. Eissenberg, T., Smith-Simone, S., Blank, M., Kleykamp, B., Sams, C., Shaffer, D., Austin, J., Gray, J., Maziak, W., & Ward, K.D. (2007, February). *U.S. waterpipe users' knowledge, beliefs, and attitudes*. Poster presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
31. Smith-Simone, S., Maziak, W., Ward, K.D., & Eissenberg, T., (2007, February). *Waterpipe use on U.S. college campuses*. Poster presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
32. Maziak, W., Rastam, S., Eissenberg, T., & Ward, K.D. (2007, February). *Waterpipe associated particulate matter emissions*. Poster presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
33. Gray, J., Sams, C., & Eissenberg, T. (2007, February). *Evaluating the acute effects of potential reduced exposure products for smokeless tobacco users: a preliminary report*. Poster presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
34. O'Connor, R., Blank, M., Caruso, R., & Eissenberg, T. (2007, February). *Influence of laboratory human smoking conditions on tar staining intensity and patterns*. Poster presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
35. Breland, A. B., Heckman C., Ingersoll, K., & Eissenberg, T. (2007, February). *Characteristics of adolescent occasional smokers*. Poster presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
36. Eissenberg, T. (2006, December). *Psychologists and IRBs: Working Collaboratively to Protect Research Participants*. Paper presented at the American Psychological Association Science Leadership Conference, Washington, DC.

37. Eissenberg, T. (2006, July). *The time for tobacco industry-sponsored PREP evaluation has arrived*. Paper presented at The 13th World Conference on Tobacco OR Health.
38. Rastam, S., Eissenberg, T., Maziak, W., & Ward, K.D. (2006, July). *Dependence, withdrawal and withdrawal suppression in waterpipe smokers*. Poster session presented at The 13th World Conference on Tobacco OR Health, Washington, DC.
39. Shihadeh, A.L., Rastam, S., Katurji, M., Maziak, W., Eissenberg, T., & Ward, K.D. (2006, July). *Effect of smoke CO concentration and overall puff duration on CO boost in waterpipe smokers: direct evidence linking toxicant exposure and uptake*. Paper presented at The 13th World Conference on Tobacco OR Health, Washington, DC.
40. Asfar, T., Ward, K.D., Maziak, W., Eissenberg, T., & Vander Weg, M.W. (2006, July). *Assessing and Treating Tobacco Use in Syrian Primary, Design and Methods*. Poster session presented at The 13th World Conference on Tobacco OR Health, Washington, DC.
41. Eissenberg, T. (May, 2006). *Importance of Tobacco Industry Sponsored PREP Evaluation*. Paper presented at the 91st Annual Meeting of the Tobacco Merchants Association, Williamsburg, VA. [Honorarium refused]
42. Abrams, K., Dorflinger, L., O'Connor, K., Wyand, A., Duffy, A., Snyder, M., Blank, M., & Eissenberg, T. (2006, March). *Suffocation fear moderates the relationship between smoking status and panic responding to a carbon dioxide challenge*. Poster presented at the 26th annual convention of the Anxiety Disorder Association of America.
43. Blank, M.D., Weaver, M.F., Sams, C.L., Kleykamp, B.A., Martin, B., & Eissenberg, T. (2006, June). *Challenges and outcomes in comparing smoked marijuana and oral THC*. Poster presented at 68th Annual Meeting of the College on Problems of Drug Dependence.
44. Kleykamp, B. A., Jennings, J.M., Sams, C.L., Blank, M.D., Weaver, M., & Eissenberg, T. (2006, June). *What are the specific cognitive effects of transdermal nicotine and smoking, and do they depend on smoker's gender?* Poster presented at the 68th Annual Meeting of the College on Problems of Drug Dependence.
45. Blank, M.D. & Eissenberg, T. (2006, February). *Do mouthpiece-based topography measurement devices alter puff topography?* Poster presentation to the 12th Annual Meeting of the Society for Research on Nicotine and Tobacco, Orlando, FL.
46. Gray, J., Breland, A., Opilla, A., & Eissenberg, T. (2006, February). *Evaluating potential reduced exposure products for smokeless tobacco users in the clinical laboratory: a preliminary report*. Poster presentation to the 12th Annual Meeting of the Society for Research on Nicotine and Tobacco, Orlando, FL.
47. Kleykamp, B. A., Jennings, J.M., Weaver, M.F., Sams, C., Blank, M.D., Opilla, A., Shaffer, D., Gray, J, Beylotte, F., & Eissenberg, T. (2006, February). *Influence of transdermal nicotine on withdrawal and smoking effects: A gender comparison*. Poster presentation to the 12th Annual Meeting of the Society for Research on Nicotine and Tobacco, Orlando, FL.
48. Kleykamp, B. A., Blank, M.D., Jennings, J.M., Weaver, M.F., & Eissenberg, T. (2005, June). *Dose dependent effects of transdermal nicotine on working memory in abstinent smokers*. Poster session at the 67th Annual Meeting of The College on Problems of Drug Dependence, June.

49. Kleykamp, B.A., Weaver, M.F., Jennings, J., Blank, M., Gray, J., White, K., Sams, C., & Eissenberg, T. (2005, February). *Does transdermal nicotine reduce the effects of a concurrently administered cigarette?* Poster session at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
50. Evans, S.E., Weaver, M.F., Sams, C., White, K., Gray, J., Collins, R., & Eissenberg, T. (2005, February). *Transdermal nicotine-induced withdrawal suppression in smokers: a gender comparison.* Poster session at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
51. Rastam, S., Maziak, W., Ward, K., & Eissenberg, T. (2005, February). *Abstinence-induced withdrawal and withdrawal suppression in Syrian smokers.* Poster session at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
52. Fouad, F.M., Ward, K.D., Eissenberg, T., Rastam, S., & Maziak, W. (2005, February). *Association between smoking and treatment outcomes in patients with pulmonary tuberculosis in Aleppo, Syria.* Poster session at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
53. Asfar, T., Ward, K.D., Vander Weg, M.W., Hammal, F., Eissenberg, T., & Maziak, W. (2005, February). *Characteristics of completers and drop-outs in Syria's first smoking cessation trial.* Poster session at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
54. Maziak, W., Ward, K.D., & Eissenberg, T. (2005, February). *Epidemiology of smoking among adults in Aleppo-Syria: the 1st population-based estimates.* Poster session at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
55. Breland, A.B., Kleykamp, B.A., Opilla, A.J., & Eissenberg, T. (2005, February). *Evaluating potential reduced exposure products (PREPs) for smokers.* Paper presented at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
56. Hammal F., Ward K.D., Eissenberg T., & Maziak W. (2005, February). *Perceptions and attitudes toward anti-smoking advertisements in Syria.* Poster session at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
57. Hammal F., Ward K.D., Eissenberg T., & Maziak W. (2005, February). *Quitting attitude among waterpipe smokers in Syria.* Poster session at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, February, 2005.
58. Evans, S.E., Weaver, M.F., Collins, R.J., & Eissenberg, T. (2004, February). *Transdermal nicotine-induced withdrawal suppression in smokers: a dose comparison.* Paper presented at the 10th Annual Meeting of the Society for Research on Nicotine and Tobacco, Scottsdale, AZ.
59. Ward, K.D., Vander Weg, M.W., Hammal, F., Maziak, W., & Eissenberg, T. (2004, February). *Factors related to interest in narghile cessation.* Paper presented at the 10th Annual Meeting of the Society for Nicotine and Tobacco Research, Scottsdale, AZ.

60. Kassel, J.D., Greenstein, J., Wardle, M., Yates, M., Evatt, D., Eissenberg, T., & Drobes, D. (2004, February). *Evidence for nicotine compensation in adolescent smokers*. Poster session at the 10th Annual Meeting of the Society for Research on Nicotine and Tobacco, Scottsdale, AZ.
61. Anderson, L., Maziak, Ward, K.D., & Eissenberg, T. (2004, February). *Do Non-U.S. cigarettes deliver the same nicotine doses as U.S. cigarettes?* Poster session at the 10th Annual Meeting of the Society for Research on Nicotine and Tobacco, Scottsdale, AZ
62. Kleykamp, B.A., Jennings, J.M., Blank, M.D., & Eissenberg, T. (2004, February). *What are the cognitive effects of nicotine in non-tobacco users?* Poster session at the 10th Annual Meeting of the Society for Research on Nicotine and Tobacco, Scottsdale, AZ.
63. Eissenberg, T. (December, 2003). *Potential Reduced Exposure Products for Tobacco Users: What Do We Know and What Do We Need to Know?* Paper presented at the National Conference on Tobacco or Health, Boston, MA.
64. Eissenberg, T. (2003, December). *Potential Reduced Exposure Products (PREPs) for Tobacco Users: What Are They and What Do They Do?* Paper presented at the National Conference on Tobacco or Health, Boston, MA.
65. Eissenberg, T., Rastoum S., Maziak W., & Ward, K. (2003, August). *The Syrian Center for Tobacco Studies: role of the clinical behavioral pharmacology laboratory*. Paper presented at the 12th World Conference on Tobacco or Health, Helsinki, Finland.
66. Ward, K.D., Maziak W., Vander Weg, M.W., Eissenberg T., & Read M.C. (2003, August). *Developing smoking cessation interventions for the Eastern Mediterranean*. Paper presented at the 12th World Conference on Tobacco or Health, Helsinki, Finland.
67. Fouad FM, Hammal, F., Ward, K.D., Eissenberg, T., Klesges R.C., & Keil, U. (2003, August). *Adapting smoking cessation intervention for developing countries: a model for the middle east*. Poster presented at the 12th World Conference on Tobacco or Health, Helsinki, Finland.
68. Ward, K.D., Maziak, W., & Eissenberg, T. (2003, August). *Status report on the Syrian Center for Tobacco Studies*. Paper presented at the 12th World Conference on Tobacco or Health, Helsinki, Finland.
69. Maziak, W., Hammal, F., Asfar, T., Ward, K.D., Eissenberg, T., Klesges R., & Keil, U. (2003, August). *The Syrian Center for Tobacco Studies: a model of international partnership for the creation of sustainable research capacity in developing countries*. Poster presented at the 12th World Conference on Tobacco or Health, Helsinki, Finland.
70. Blank, M., Kleykamp, A., Campbell T., Breland, A., Jennings, J., & Eissenberg, T. (2003, February). *Does caffeine influence nicotine's effects?* Poster session at the Ninth Annual Meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA.
71. Breland A., Buchhalter A.R., & Eissenberg, T. (2003, February). *Do reduced exposure products actually reduce exposure? Nitrosamine levels in Advance users*. Poster presentation to the Ninth Annual Meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA.
72. Evans, S.E. & Eissenberg, T. (2003, February). *Do brand-induced changes in puff topography occur outside of the laboratory?* Poster presentation to the Ninth Annual Meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA.

73. Evans, S.E., Breland A., Kleykamp A., Buchhalter A.R., & Eissenberg, T. (2003, February). *Ambulatory puff topography measurement: a validation study*. Poster presentation to the Ninth Annual Meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA.
74. Hamilton, D.C.P., Buchhalter A.R., & Eissenberg, T. (2003, February). *Urine cotinine as an index of smoking status: comparison of GC/MS with immunoassay test strips*. Poster presentation to the Ninth Annual Meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA.
75. Buchhalter A.R., Breland, A., Evans S.E., & Eissenberg, T. (2002, June). *Symptoms and signs of nicotine withdrawal in smokers: a placebo control study*. Oral presentation to the 64th Annual Meeting of the College on Problems of Drug Dependence.
76. Breland, A.B., Hyder N., Evans S.E., Buchhalter A., & Eissenberg, T. (2002, February). *Acute effects of Advance: a potential reduced exposure product for smokers*. Poster presentation to the Eighth Annual Meeting of the Society for Research on Nicotine and Tobacco, Savannah, GA.
77. Corrigan, W.A., Zack, M., & Eissenberg, T. (2002, February). *Laboratory research with adolescent cigarette smokers*. Paper presentation to the Eighth Annual Meeting of the Society for Research on Nicotine and Tobacco, Savannah, GA.
78. Buchhalter A., Breland, A.B., Evans S.E., & Eissenberg, T. (2002, February). *A Placebo control study of nicotine withdrawal in cigarette smokers*. Poster presentation to the Eighth Annual Meeting of the Society for Research on Nicotine and Tobacco, Savannah, GA.
79. Eissenberg, T. (2001, August). *Ethical Issues for Substance Use Research With Children and Adolescents*. Paper presented to the 109th Annual Convention of the American Psychological Association. San Francisco, CA.
80. Breland, A., Buchhalter A., Evans S., & Eissenberg, T. (2001, March). *Comparison of the withdrawal suppression, physiological effects, and nicotine delivery of two novel smoking systems*. Poster session at the Seventh Annual Meeting of the Society for Research on Nicotine and Tobacco.
81. Breland, A., Buchhalter A., Evans S., & Eissenberg, T. (2001, June). *Comparison of the withdrawal suppression, physiological effects, and nicotine delivery of two novel smoking systems*. Poster presented at the 63rd Annual Meeting of the College on Problems of Drug Dependence.
82. Buchhalter, A., Karpf, A.S., & Eissenberg, T. (2000, February). *Gender differences and smoking-related stimuli: a laboratory study*. Poster presentation to the Sixth Annual Meeting of the Society for Research on Nicotine and Tobacco, Crystal City, VA.
83. Eissenberg, T. (2000, February). *Initial Tobacco Use Episodes in Children and Adolescents: Current Knowledge, Future Directions*. Sixth Annual Meeting of the Society for Research on Nicotine and Tobacco, Crystal City, VA.
84. Gire J.T. & Eissenberg, T. (2000, February). *Placebo Control Study of Acute Smokeless Tobacco Abstinence*. Poster session at the Sixth Annual Meeting of the Society for Research on Nicotine and Tobacco, Crystal City, VA.

85. Zack, M., Belisto, L., Scher, R., Corrigan, W.A., & Eissenberg, T. (2000, February). Effects of smoking severity and gender on Stroop interference to smoking-related words in adolescent smokers. Poster presentation to the Sixth Annual Meeting of the Society for Research on Nicotine and Tobacco, Crystal City, VA.
86. Corrigan, W.A., Zack, M., Belisto, L., Scher, R., & Eissenberg, T. (1999, November). *Topography and subjective effects of smoking in adolescent cigarette smokers*. Paper Presented to the second annual scientific meeting of the International Society for Research on Nicotine and Tobacco, London, England.
87. Eissenberg, T. *A Clinical Laboratory Model for Direct Assessment of Medication-Induced Antihyperalgesia and Subjective Effects: Initial Validation Studies*. Workshop presentation to the 61st annual scientific meeting of the College on Problems of Drug Dependence, Acapulco, Mexico, June, 1999.
88. Eissenberg, T., Adams, C., & Riggins, E.C. III. *Women tobacco smokers are more sensitive than men to the subjective effects but not the physiological effects of tobacco cigarette smoking*. Poster presentation to the 61st annual scientific meeting of the College on Problems of Drug Dependence, Acapulco, Mexico, June, 1999.
89. Buchhalter, A., & Eissenberg, T. *Reduced CO boost produced in humans smoking a novel smoking system*. Poster presentation to the Fifth Annual Meeting of the Society for Research on Nicotine and Tobacco, March 5-7, 1999.
90. Eissenberg, T., Riggins E.C., III, & Weaver, M.F. *Acute effects of mecamylamine and nicotine combinations in smokers: puff topography and subjective craving*. Poster presentation to the Fifth Annual Meeting of the Society for Research on Nicotine and Tobacco, March 5-7, 1999.
91. Zack, M., Belisto, L., Scher, R., Eissenberg, T., & Corrigan, W.A. *Smoking a cigarette reduces Stroop interference to smoking words in adolescent smokers*. Poster presentation to the Fifth Annual Meeting of the Society for Research on Nicotine and Tobacco, March 5-7, 1999.
92. Eissenberg, T. (1998, October). *Heroin dependence treatment research: human subjects in the clinic and the laboratory*. Paper presented at the Addiction Research Foundation, Toronto, Ontario, Canada. [Invited Address].
93. Eissenberg, T. (1998, September). *Heroin dependence treatment research: human subjects in the clinic and the laboratory*. Presented to the McMaster University Psychology Department, Hamilton, Ontario, Canada. [Invited Address].
94. Eissenberg, T. (1998, August). *LAAM and Methadone: Relative Potency and Acute Physical Dependence in Humans*. Paper presented at the 106th annual convention of the American Psychological Association, San Francisco, CA.
95. Eissenberg, T., Stitzer, M.L., Bigelow, G.E., Buchhalter, A.R., & Walsh, S.L. (1998, June). *Comparison of acute physical dependence duration in humans after single doses of LAAM or methadone*. Poster session at the 60th annual scientific meeting of the College on Problems of Drug Dependence, Scottsdale, AZ.
96. Eissenberg, T., Kennedy, K., Riggins, E.C. III, & Likness, M.A. (1998, March). *PC-based concurrent measurement of puff topography and physiological and subjective effects: objective validation and sex differences in cigarette smokers*. Poster session at the 4th Annual meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA.

97. Johnson, R.E., Eissenberg, T., Strain, E.C., Walsh, S.L., & Bigelow, G.E. (1997, June). *Dose comparison of LAAM during maintenance therapy*. Presented to the 59th annual scientific meeting of the College on Problems of Drug Dependence, Nashville, TN.
98. Eissenberg, T., Stitzer, M.L., Bigelow, G.E., Buchhalter, A.R., & Walsh, S.L. (1997, June). *LAAM is not less potent than methadone: a relative potency comparison of acute agonist effects*. Poster session at the 59th annual scientific meeting of the College on Problems of Drug Dependence, Nashville.
99. Johnson, R.E., Eissenberg, T., Strain, E.C., Walsh, S.L., Brooner, R.K., Liebson, I.A., Stitzer, M.L., & Bigelow, G.E. (1996, March). *LAAM dose comparison: a clinical trial*. Presented to the 98th annual meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, CA.
100. Eissenberg, T., Liebson, I.A., & Stitzer, M.L. (1996, June). *Time course of naloxone-precipitated withdrawal after acute buprenorphine exposure in humans*. Poster session at the 58th annual scientific meeting of the College on Problems of Drug Dependence, San Juan, PR.
101. Stitzer, M.L., Eissenberg, T., Liebson, I.A., & Johnson, R.E. (1996, June). *Relative potency of naltrexone and naloxone in precipitating withdrawal in humans*. Poster session at the 58th annual scientific meeting of the College on Problems of Drug Dependence, San Juan, PR.
102. Bigelow, G.E., Eissenberg, T., Stitzer, M.L., Walsh, S.L., Liebson, I.A., Strain, E.C., & Johnson, R.E. (1996, June). *Less-than-daily buprenorphine dosing*. Poster session at the 58th annual scientific meeting of the College on Problems of Drug Dependence, San Juan, PR.
103. Johnson, R.E., Eissenberg, T., Strain, E.C., Walsh, S.L., Stitzer, M.L., Brooner, R.K., Liebson, I.A., & Bigelow, G.E. (1996, June). *Rapid LAAM induction in an outpatient clinical trial*. Poster session at the 58th annual scientific meeting of the College on Problems of Drug Dependence, San Juan, PR.
104. Johnson, R.E., Eissenberg, T., Bigelow, G.E., Walsh, S.L., Liebson, I.A., Strain, E.C., & Stitzer, M.L. (1996, March). *A pilot study of less-than-daily-dosing*. Poster session at the 97th annual meeting of the American Society for Clinical Pharmacology and Therapeutics, Lake Buena Vista, FL.
105. Eissenberg, T., Griffiths, R.R., Liebson, I.A., Lichtman, D., & Stitzer, M.L. (1995, March). *Mecamylamine does not precipitate withdrawal in cigarette smokers*. Paper presented to the 2nd annual meeting of the Society for Research on Nicotine and Tobacco, Washington, DC.
106. Eissenberg, T., Greenwald, M., Johnson, R.E., Liebson, I.A., Bigelow, G.E., & Stitzer, M.L. (1995, June). *Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal*. Poster session at the 57th annual scientific meeting of the College on Problems of Drug Dependence, Scottsdale, AZ.
107. Johnson, R.E., Eissenberg, T., Alim, T.N., Vocci, F.J., Risher-Flowers, D.J., & Deutsch, S.I. (1995, June) *Comparison of the withdrawal syndromes following abrupt termination of buprenorphine and methadone*. Paper presented at the 57th annual scientific meeting of the College on Problems of Drug Dependence, Scottsdale, AZ.
108. Siegel, S., Allan, L.G., & Eissenberg, T. (1995, July). *What does contingently elicit "contingent" color aftereffects?* Paper presented at the First International Conference of the Australian Learning Group, Townsville, North Queensland, Australia.

109. Allan, L.G., Siegel, S., Eissenberg, T., & Thomas, S.E. (1995, July). *What elicits the Indirect ME?* Paper presented to the Cognitive Science Association for Interdisciplinary Learning, Hood River, OR.
110. Eissenberg, T., Allan, L.G., Siegel, S. & Petrov, N. (1993, November). *Stimulus generalization and the indirect McCollough effect.* Paper presented at the 34th annual meeting of the Psychonomic Society, Washington, D.C.
111. Eissenberg, T., Allan, L.G., Siegel, S. & Petrov, N. (1993, July). *When do non-orthogonal grids elicit color aftereffects?* Paper presented at the 3rd annual meeting of the Canadian Society for Brain, Behaviour, and Cognitive Science, Toronto, Ontario, Canada.
112. Eissenberg, T., Allan, L.G., & Siegel, S. (1993, April). *How indirect is the "indirect" McCollough Effect?* Paper presented at the 64th annual meeting of the Eastern Psychological Association Arlington, VA.
113. Allan, L.G., Siegel, S. & Eissenberg, T. (1991, November). *Contingency manipulations and the McCollough effect.* Paper presented at the meeting of the Psychonomic Society, San Francisco, CA.
114. Eissenberg, T. (1989, June). *An Evaluation of ERIC/TM's Review Process.* Paper presented to the National Council on Measurement in Education, San Francisco, CA.

Teaching History

Virginia Commonwealth University, Richmond, Virginia. (b) (6)

Grantwriting (PSYC 700)

Fall, 2009: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Fall, 2007: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Fall, 2006: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Fall, 2005: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Fall, 2004: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Fall, 2003: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Application of Statistics (PSYC 214).

Spring 2001: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Spring 2000: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Spring 1999: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Spring 1998: Evaluation results (mean): Course = [redacted], Instructor = [redacted], Learning = [redacted].

Special Topics: Grant-writing (PSYC 691).

Fall, 2002: Evaluation results not available.

Fall, 2001: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Fall, 2000: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Fall, 1998: Evaluation results (mean): Course = [redacted]; Instructor = [redacted]; Learning = [redacted].

Drug Dependence (PMC 548), Guest lecturer each semester from Spring 1998 to 2002.

Mount Allison University, Sackville, New Brunswick, Canada.

Neuropharmacology, Winter, 1994. Evaluation results not available.

Psychological Processes (Introduction to Psychology), Winter, 1994. Overall rating = [redacted].

Advanced Experimental Design and Analysis, Fall, 1993. Overall rating = [redacted].

Principles of Conditioning, Fall 1993. Overall rating = [redacted].

McMaster University, Hamilton, Ontario, Canada.

Research Design and Statistics II, Summer, 1993. Evaluation results not available.

Research Design and Statistics I, Summer, 1993. Evaluation results not available.

Principles of Conditioning, Summer, 1992. Effectiveness = [redacted].

- Departmental Service** Biopsychology Program Director, Spring 2004 to 2009.
Department of Psychology/Massey Cancer Center Search Committee (area open, Dr. S. Danish, Chair).
2005-2007.
Personnel Committee (Dr. Everett Worthington, Chair). 2002-2004.
Department of Psychology Faculty Search Committee (area open; Dr. S. Vrana, Chair), 2004.
Dr. Mary Loos Promotion Committee (Dr. B. Myers, Chair), 2004.
Dr. Christy Porter Promotion Committee (Chair), 2003.
Dr. Jean Corcoran Promotion Committee (Dr. P. Garner, Chair), 2003.
Biopsychology Faculty Search Committee (Dr. Robert Hamm, Chair). 2000-2001.
Institute for Drug and Alcohol Studies Search Committee (Dr. Sid Schnoll, Chair). 1998-1999.
Dr. Dace Svikis Tenure Committee (non-voting member), 1999.
Ad Hoc Review Committee for the Drug Abuse Small Grants Program for the NIDA Drug Abuse Research Center at VCU, 1999.
- University Service** Institutional Review Board, Panel B, 2007-present
Institutional Review Board, Panel A, 2000-2007
Conflict of Interest Committee, Dr. Richard Franson, Chair. 2003-2005.
IRB Prioritization Committee, Dr. John Clore, Chair. 1999-2000.
Pain Management Task Force (and Research Subcommittee), Dr. Sid Schnoll, Chair. 1999.
Tobacco Settlement Planning and Strategy Session, April 28, 1999.
- Professional Service** Ad Hoc Reviewer
New England Journal of Medicine
Nicotine and Tobacco Research
Tobacco Control
- Masthead Editorial Boards
Clinical Pharmacology and Therapeutics (ended 2006).
Experimental and Clinical Psychopharmacology (ended 2010)
Psychology of Addictive Behavior (ended 2002).
- NIH Grant Review
NIDA's Conference Grant Applications (R13). July 28, 2009.
ZRG1 BBBP-T. July 30, 2009.
ZRG1 RPHB-A (58) R meeting. July 20, 2009.
BBBP-C. October 28, 2008.
ZRG1 RPIA-H. October 26-27, 2006.
BRLE. October 15-17, 2003.
BBBP-1. February 10-12, 2003.
Medication Development Centers, Special Emphasis Panel, ZDA1 KXA-N (27). March 10-11, 1999.
Strategic Program for Innovative Research on Cocaine (and Other Psychomotor Stimulants) Addiction Pharmacotherapy, Special Emphasis Panel ZDA1 KXA-N (18). November 16, 1999.
National Institute on Drug Abuse "Behavioral Science Track Awards for Rapid Transition (B/START, PAR-97-046)".
- Scientific Societies
Chair, Committee on Human Research. American Psychological Association. March 2010 to present.
Chair, Presidential Task Force on Institutional Review Boards and Psychological Science. American Psychological Association. September 2006 to December 2007.
Member, Ad Hoc Committee to Advance Research. American Psychological Association. February 2006 to present.

Member, Policy Committee, Society for Research on Nicotine and Tobacco, 2007 – present.
Member, Product Track Program Subcommittee. 13th World Conference on Tobacco or Health. Committee Member. May 2004-July, 2006.
Program and Training Council Chair, Society for Research on Nicotine and Tobacco, March, 2003 – February 2006.
Co-Chair, Program Committee, Society for Research on Nicotine and Tobacco, April, 2002 – February, 2003. (with Dr. Laura Klein).
Chair, Program Committee, Society for Research on Nicotine and Tobacco, April, 2001 – February, 2002.
Co-Chair, Program Committee, Society for Research on Nicotine and Tobacco, April, 2000 – February, 2001. (with Dr. David Wetter).
Member, Human Research Committee, College on Problems of Drug Dependence. June, 1999 - June 2002.
Member, Program Committee, Society for Research on Nicotine and Tobacco, April, 1999 – February 2000.

Personal Information

Birth date: (b) (6)
Birthplace: (b) (6)
Country of Citizenship: (b) (6)
Family status: (b) (6)

References

(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)